2024 ASCO Annual Meeting The American Society of Clinical Oncology assumes no responsibility for errors or omissions in this publication. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration or administration, or contraindications.

It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient

2024 ASCO Annual Meeting Abstracts

GuidetoAbstracts
PlenarySession…………………………………………………………………………………………………………………………………………………………. 1s
SpecialClinicalScienceSymposia……………………………………………………………………………………………………………………………… 3s
BreastCancer—Local/Regional/Adjuvant…………………………………………………………………………………………………………………… 6s
BreastCancer—Metastatic………………………………………………………………………………………………………………………………………… 39s
CareDelivery/ModelsofCare…………………………………………………………………………………………………………………………………….. 75s
CentralNervousSystemTumors……………………………………………………………………………………………………………………………….. 112s
DevelopmentalTherapeutics—Immunotherapy…………………………………………………………………………………………………………. 138s
DevelopmentalTherapeutics—MolecularlyTargetedAgentsandTumorBiology………………………………………………………… 188s
GastrointestinalCancer—ColorectalandAnal……………………………………………………………………………………………………………. 234s
GastrointestinalCancer—Gastroesophageal,Pancreatic,andHepatobiliary………………………………………………………………… 270s
GenitourinaryCancer—KidneyandBladder……………………………………………………………………………………………………………….. 323s
GenitourinaryCancer—Prostate,Testicular,andPenile……………………………………………………………………………………………… 355s
GynecologicCancer…………………………………………………………………………………………………………………………………………………… 388s
HeadandNeckCancer……………………………………………………………………………………………………………………………………………….424s
HematologicMalignancies—Leukemia,MyelodysplasticSyndromes,andAllotransplant…………………………………………….457s
HematologicMalignancies—LymphomaandChronicLymphocyticLeukemia……………………………………………………………. 481s
HematologicMalignancies—PlasmaCellDyscrasia…………………………………………………………………………………………………….506s
LungCancer—Non–SmallCellLocal-Regional/SmallCell/OtherThoracicCancers……………………………………………………..524s
LungCancer—Non–SmallCellMetastatic…………………………………………………………………………………………………………………. 557s
MedicalEducationandProfessionalDevelopment………………………………………………………………………………………………………599s
Melanoma/SkinCancers……………………………………………………………………………………………………………………………………………. 613s
PediatricOncology…………………………………………………………………………………………………………………………………………………….642s
Prevention,RiskReduction,andGenetics…………………………………………………………………………………………………………………..662s
QualityCare/HealthServicesResearch……………………………………………………………………………………………………………………….692s
Sarcoma……………………………………………………………………………………………………………………………………………………………………. 739s
SymptomScienceandPalliativeCare…………………………………………………………………………………………………………………………762s